Delving into the Latest Updates on CLT-28643 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

α5β1

Mechanism

α5β1 antagonists(Integrin alpha-5/beta-1 antagonists)

Therapeutic Areas

Congenital DisordersEye DiseasesOther Diseases

Active Indication

FibrosisOcular HypertensionWet age-related macular degeneration+ [1]

Inactive Indication-

Originator Organization

ClanoTech AB

Active Organization

ClanoTech ABSuzhou Clanotech Biopharm Ltd

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

PurposeTo evaluate the therapeutic potential of the small molecule integrin α5β1 inhibitor, CLT-28643, to improve the filtering surgery outcome in a mouse model. Different dose regimens and administration routes of the inhibitor were compared with mitomycin C (MMC), the gold standard in clin ical practice.MethodsThe efficacy of CLT-28643 on surgical outcome was studied in a mouse model for filtering surgery (n = 40 eyes from 20 mice per group). Single and repeated subconjunctival (SCJ) injections (1 or 2 μg) and topical eye drops (10 μg) of the integrin inhibitor were compared with 2-minute administration of MMC 0.02%. Bleb size, survival, and signs of toxicity were examined until 28 days after surgery. Immunohistochemical analysis of angiogenesis, inflammation, collagen deposition, and integrin α5β1 expression were performed on postoperative days 3, 8, 14, and 28. A masked observer performed all the assessments.ResultsImmunostaining showed that integrin α5β1 was highly expressed in the bleb at early time-points after surgery and that CLT-28643 inhibited this upregulation. Efficacy was shown to be dose-dependent for the integrin inhibitor CLT-28643 for bleb area and survival, and the wound healing process. While 2-μg single injection of CLT-28643 improved bleb characteristics in a similar way as 10-μg administered by eye drops and MMC, repeated injections of 2 μg showed superior efficacy compared to MMC, with no corneal toxicity.ConclusionsAdministration of the integrin α5β1 inhibitor CLT-28643 has therapeutic potential as an adjunct to glaucoma surgery, possibly with a superior efficacy and tolerability compared with MMC when used at the optimal dose.

100 Deals associated with CLT-28643

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fibrosis	Preclinical	SE	ClanoTech AB	-
Ocular Hypertension	Preclinical	SE	ClanoTech AB	-
Wet age-related macular degeneration	Preclinical	SE	ClanoTech AB	-
Cicatrix	Discovery	US	ClanoTech AB	-
Cicatrix	Discovery	CN	Suzhou Clanotech Biopharm Ltd	-